Use of raloxifene for preparing medicine for treating, fibroid and endometriosis
OA: closed
AI-generated summary
This patent describes administering 30-150 mg/day of raloxifene or its salts to prevent uterine myoma development and relieve endometriosis symptoms in women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The invention refers to the prevention and cure of hystero myoma and the treatment of endometriosis. Give Raloxifen or its salt receivable in medicine about 30-150mg/day to women suffering from myoma of uterus, to prohibit the development of hystero myoma. Give Raloxifen or its salt receivable in medicine about 30-150mg/day to women in procreating period, to relieve the symptom of endometriosis.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-10-11T09:27:45.537177+00:00